Literature DB >> 11044361

High tPA-expression in primary melanoma of the limb correlates with good prognosis.

C M Ferrier1, S Suciu, W L van Geloof, H Straatman, A M Eggermont, H S Koops, B B Kroon, F J Lejeune, U R Kleeberg, G N van Muijen, D J Ruiter.   

Abstract

To investigate whether the course of primary melanoma disease correlates with expression of the various components of the proteolytic plasminogen activation (PA) system, immunohistochemical stainings for activators of plasminogen (tissue type (tPA) and urokinase type (uPA)), inhibitors of plasminogen activation (type 1 (PAI-1) and type 2 (PAI-2)) and the receptor for uPA (uPAR) were performed on 214 routinely processed melanoma lesions. All lesions were primary cutaneous melanomas, minimally 1.5 mm thick, and derived from patients with only local disease at the moment of diagnosis (clinically stage II (T(3-4)N(0)M(0)), American Joint Committee on Cancer). Median patient follow-up was 6.1 years. Single variables as immunohistochemical staining results (extent of tumour cell staining, pattern of tumour cell staining and for some components also staining of stromal cells), histopathological and clinical parameters as well as treatment variables were analysed in order to assess their prognostic importance, in terms of time to recurrence, time to distant metastasis and duration of survival. The extent of tPA tumour cell positivity, categorized as 0-5%, 6-50% and 51-100%, appeared to be of importance for these end-points. Lesions with 51-100% tPA-positive tumour cells were found to have the best prognosis, whereas lesions with 6-50% tPA-positive tumour cells had the worst. Moreover, the prognostic significance of Breslow thickness, microscopic ulceration and sex was confirmed in this study. Multivariate analyses, incorporating these relevant factors, showed that the extent of tPA tumour cell positivity was an independent prognostic factor for distant metastasis-free interval (P = 0.012) and for the duration of survival (P = 0.043). Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044361      PMCID: PMC2408793          DOI: 10.1054/bjoc.2000.1460

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  62 in total

1.  Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells.

Authors:  M Cardinali; R Uchino; S I Chung
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

2.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

3.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited.

Authors:  F R Rickles; R L Edwards
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

4.  The role of hemostasis and fibrinolysis in the metastatic spread of cancer.

Authors:  G Markus
Journal:  Semin Thromb Hemost       Date:  1984-01       Impact factor: 4.180

5.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

6.  Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.

Authors:  Y Takeuchi; A Nakao; A Harada; T Nonami; T Fukatsu; H Takagi
Journal:  Am J Gastroenterol       Date:  1993-11       Impact factor: 10.864

7.  Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.

Authors:  A Meissauer; M D Kramer; V Schirrmacher; G Brunner
Journal:  Exp Cell Res       Date:  1992-04       Impact factor: 3.905

8.  Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro.

Authors:  Y Sato; K Okamura; A Morimoto; R Hamanaka; K Hamaguchi; T Shimada; M Ono; K Kohno; T Sakata; M Kuwano
Journal:  Exp Cell Res       Date:  1993-02       Impact factor: 3.905

9.  Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.

Authors:  P H Quax; G N van Muijen; E J Weening-Verhoeff; L R Lund; K Danø; D J Ruiter; J H Verheijen
Journal:  J Cell Biol       Date:  1991-10       Impact factor: 10.539

10.  Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.

Authors:  J Yamashita; M Ogawa; S Yamashita; Y Nakashima; T Saishoji; K Nomura; K Inada; I Kawano
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more
  6 in total

1.  The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity.

Authors:  Denis Gingras; Dominique Labelle; Carine Nyalendo; Dominique Boivin; Michel Demeule; Chantal Barthomeuf; Richard Béliveau
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

Review 2.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

3.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

Review 4.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

5.  Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.

Authors:  Karin Abbink; Petra L M Zusterzeel; Anneke Geurts-Moespot; Rob van der Steen; Paul N Span; Fred C G J Sweep
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-11       Impact factor: 4.553

6.  OSskcm: an online survival analysis webserver for skin cutaneous melanoma based on 1085 transcriptomic profiles.

Authors:  Lu Zhang; Qiang Wang; Lijie Wang; Longxiang Xie; Yang An; Guosen Zhang; Wan Zhu; Yongqiang Li; Zhihui Liu; Xiaochen Zhang; Panpan Tang; Xiaozheng Huo; Xiangqian Guo
Journal:  Cancer Cell Int       Date:  2020-05-19       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.